Recently Visited
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
Most Searched
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} |
Score {{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
Search results for {{searchTermHome}}
{{scheme.stockprice}}
{{scheme.chgp}}%
{{scheme.chgp}}%
{{scheme.scoreText}} | Score
{{scheme.score}}
{{scheme.score}}
{{scheme.scoretext}}
{{ scheme.tag }}
No Matches Found
No Matches Found
Lixte Biotechnology Holdings, Inc.
Is Lixte Biotechnology Holdings, Inc. overvalued or undervalued?
Loading...
Is Lixte Biotechnology Holdings, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data to assess the current stance of Lixte Biotechnology Holdings, Inc.
What does Lixte Biotechnology Holdings, Inc. do?
Lixte Biotechnology Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net loss of $1 million and a market cap of $2.98 million. It has no dividend yield and negative financial metrics, including a debt equity ratio of -1.19 and a return on equity of -286.78%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
![]( "Upgrade & View All Insights")
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read